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ABSTRACT 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovitis, progressive 
joint destruction, and disability. Reactive arthritis (ReA) is a sterile joint inflammation 
following a distant mucosal infection. The clinical course of these diseases is variable and 
cannot be predicted with reasonable accuracy by clinical and laboratory markers. 
 
The predictive value of circulating soluble interleukin-2 receptor (sIL-2R), a marker of 
lymphocyte activation, measured by Immulite® automated immunoassay analyzer, was 
evaluated in two cohorts of RA patients. In 175 patients with active early RA randomized to 
treatment with either on disease-modifying antirheumatic drug (DMARD) or a combination 
of 3 DMARDs and prednisolone, low baseline sIL-2R level predicted remission after 6 
months in patients treated with a single DMARD. In 24 patients with active RA refractory to 
DMARDs, low baseline sIL-2R level predicted rapid clinical response to treatment with 
infliximab, an anti-tumour necrosis factor antibody. Furthermore, in a cohort of 26 patients 
with acute ReA, high baseline sIL-2R level predicted remission after 6 months. 
 
Levels of circulating soluble E-selectin (sE-selectin), a marker of endothelial activation, were 
measured annually by enzyme-linked immunosorbent assay (ELISA) in a cohort of 85 
patients with early RA. During a five-year follow-up, sE-selectin levels were associated with 
activity and outcome of RA. 
 
The levels of neutrophil and monocyte CD11b/CD18 expression measured by flow cytometry, 
and circulating levels of sE-selectin measured by ELISA, and procalcitonin by 
immunoluminometric assay, were compared in 28 patients with acute ReA and 16 patients 
with early RA. The levels of the markers were comparable in ReA, RA, and healthy control 
subjects. 
 
In conlusion, sIL-2R may provide a new predictive marker in early RA treated with a single 
DMARD and refractory RA treated with infliximab. In addition, sIL-2R level predicts 
remission in acute ReA. 
11 
INTRODUCTION 
Rheumatoid arthritis (RA) is an autoimmune disease, which manifests as chronic polyarthritis 
with diverse extra-articular complications. The prevalence of RA in adult population is 
estimated at 0.8-1%, and the disease continues to cause significant morbidity, disability, and 
premature mortality. Reactive arthritis (ReA), a member of the family of 
spondyloarthropathies, is an acute, sterile joint inflammation developing after a variety of 
enteric, urogenital, or respiratory infections. The prognosis is generally good, but persistent or 
recurrent infection may contribute to progression into chronic spondyloarthropathy. 
 
The clinical course of RA varies from spontaneous remission to persistent inflammation 
resulting in joint destruction, loss of physical function, and early death. Early treatment and 
achievement of remission have been shown to be of benefit. Therefore the current therapeutic 
strategy is to start treatment with disease-modifying antirheumatic drugs (DMARDs) in all 
patients. The patients refractory to DMARDs are treated with biological response modifiers, 
which are expensive, and associated with serious, although rare, adverse effects related to 
impaired host defence. Ideally, the   choice of the therapy should be based on the predicted 
disease course and response to a given therapeutic regimen. Thus, markers are needed to 
identify the those patients who may achieve a good and prompt response with appropriate 
therapies. 
 
The present study investigates immune activation in patients with RA and ReA, and explores 
markers of immune activation as tools of differential diagnosis in acute arthritides and as 
predictors of treatment response in RA and ReA. 
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REVIEW OF LITERATURE 
Immune activation 
The immune system is an organization of cells and molecules with specialized roles in 
defending against microbes and foreign cells. There are two fundamentally different types of 
responses to invading microbes. Innate responses occur to the same extent independent of 
how many times the infectious agent is encountered and provide the early protection from 
microbial invasion. Adaptive immunity is important later on in the immune response and 
improves on repeated exposure to given infection [Parkin and Cohen 2001]. Innate and 
adaptive responses usually work together to eliminate pathogens. Antigen presenting cells, 
such as dendritic cells, present antigens along with costimulatory signals to T cells, 
facilitating the adaptive response. Antibodies secreted by B cells, resulting from an adaptive 
immune response, help phagocytes ingest pathogens. Cytokines also provide an important 
means of communication between innate and adaptive immunity. Autoimmune disease may 
emerge when there is lack of immunological tolerance to self-antigens or failure to restrict or 
down-regulate normal immune responses [Davidson and Diamond 2001]. 
Innate immunity 
Cellular components 
The phagocytes (monocytes/macrophages and neutrophils) are the principal cell types 
involved in host defence. Eosinophils, basophils, and mast cells have a less defined role in 
innate immunity, whereas they are involved in allergic reactions [Bochner and Schleimer 
2001]. Natural killer cells recognize abnormal cells, such as those infected with a virus, 
inducing apoptosis [Yokoyama et al. 2004]. 
Monocytes and macrophages 
Monocytes are the circulating precursors of tissue macrophages. They lack phagocytic 
capacity and are relatively inert whilst in the blood compartment. Once the monocyte leaves 
the circulation it differentiates into the macrophage, defined by its capacity to phagocytose. 
The phenotypic form taken by the macrophage depends on the environmental factors present 
in the tissue [Duffield 2003]. 
 
Classically activated macrophages are developed in response to interferon-γ (IFN-γ), along 
with exposure to bacterial lipoproteins, bacterial DNA, parasitic proteins/carbohydrates, 
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opsonized particles, or exogenous tumor necrosis factor (TNF). Also ligation of chemokine 
receptors, hypoxia, and abnormal collagen deposition push the macrophage towards classical 
activation phenotype. IFN-γ augments cytokine and toxic nitrogen radical release, and up-
regulates expression of receptors necessary for effective presentation of antigens to the 
adaptive immune system [Mosser 2003].  
 
Exposure to IL-4, IL-10, IL-13, transforming growth factor-β (TGF-β), or glucocorticoids 
causes macrophages to become alternatively activated, preventing the classical inflammatory 
phenotype. These macrophages generate anti-inflammatory cytokines, while the synthesis of 
pro-inflammatory cytokines is suppressed. However, they show enhanced capacity for antigen 
presentation and enhanced phagocytosis of debris and particles, though not pathogens 
[Mosser 2003]. 
Neutrophils 
Neutrophils are mobile cells that travel around the body. They normally flow freely in the 
blood or roll along the vascular endothelium (marginating pool). To home to a site of 
infection, neutrophils use a multistep process involving proinflammatory mediators, adhesion 
molecules, chemoattractants, and chemokines [Ebnet and Vestweber 1999]. 
 
The recruited neutrophils phagocytose organisms by making pseudopodia (projections of 
cytoplasmic membrane) which form a membrane-bound vesicle (phagosome) around the 
particle. This fuses with cytoplasmic granules to form the phagosome. In this protected 
compartment, killing of the organism occurs by a combination of two mechanisms. The 
oxygen-dependent response or respiratory burst involves the sequential reduction of oxygen 
by NADPH oxidase leading to production of toxic oxygen metabolites, such as hydrogen 
peroxide, hydroxyl radicals, and singlet oxygen. The oxygen-independent response uses the 
highly toxic cationic proteins and enzymes (e.g., myeloperoxidase and lysozyme) contained 
within the neutrophil cytoplasmic granules. Ingestion and killing of organisms is 100-fold 
more effective if the particle is first opsonised with specific antibody or complement. These 
molecules bind to neutrophil Fc and complement receptors, increasing adhesion between 
particle and phagocyte and priming the cell for activation [Witko-Sarsat et al. 2000]. 
Soluble components 
Cytokines 
Cytokines are small molecular weight messengers secreted by one cell to alter the behaviour 
of itself or another cell (Figure 1). The biological effect of a cytokine depends on the cytokine 
and the cell involved and its environment, but typically they affect cell activation, division, 
apoptosis, or movement. Cytokines bind to specific receptors. Most cytokines are soluble, but 
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some may also be membrane-bound. Cell-surface cytokine receptors may also be secreted in 
soluble form [Borish and Steinke 2003]. 
 
Cytokines produced by leukocytes and having effects mainly on other leukocytes are termed 
interleukins. Over 30 interleukins have been currently described. Cytokines that have 
chemoattractant activity are called chemokines. Those that cause differentiation and 
proliferation of stem cells are called colony-stimulating factors. Those that interfere with viral 
replication are called interferons. 
 
TNF is mainly produced by monocytes/macrophages, but also by neutrophils, activated 
lymphocytes, NK cells, endothelial cells, and mast cells. The most potent inducer of TNF by 
monocytes is LPS. TNF has two distinct receptors: TNFR I (p55) and TNFR II (p75). They 
have similar affinities and produce similar effects [Tartaglia and Goeddel 1992]. TNF induces 
antitumour immunity through direct cytotoxic effects on cancerous cells, hence the name 
tumour necrosis factor [Carswell et al. 1975]. On the whole, TNF stimulates general immune 
activation. TNF induces adhesion molecules (intercellular adhesion molecule-1, ICAM-1; 
vascular cell adhesion molecule-1, VCAM-1; E-selectin) on endothelial cells, permitting 
adhesion and subsequent transmigration of leukocytes. TNF activates neutrophils, mediating 
adherence, chemotaxis, degranulation and respiratory burst [Vassalli 1992]. TNF induces 
vascular leakage, and is also responsible for the severe cachexia (hence the previous name 
cachexin), which occurs in chronic infections and cancer [Beutler and Cerami 1989]. 
 
IL-1 family comprises four peptides: IL-1α, IL-1β, IL-1 receptor antagonist (IL-1ra), and IL-
18. IL-1 is primarily produced by monocytes/macrophages, but also by endothelial cells, 
keratinocytes, synovial cells, osteoblasts, neutrophils, glial cells, and numerous other cell 
types. IL-1 production can be stimulated by a variety of agents, including lipopolysaccharide 
(LPS), other cytokines, microorganisms, and antigens. IL-1 has two types of receptors (IL-
1R), type I IL-1R responsible for the proinflammatory effect of IL-1, and the inactive type II 
IL-1R thought to sequester IL-1 and thus have an anti-inflammatory function [Dinarello 
1998]. 
 
IL-1 activates T lymphocytes by enhancing the production of IL-2 and expression of IL-2 
receptors (IL-2R). It also augments B-cell proliferation and immunoglobulin synthesis. IL-1 
interacts with the central nervous system to produce fever, lethargy, sleep, and anorexia 
[Licinio and Wong 1997]. IL-1 stimulates endothelial cell adherence to leukocytes through 
the upregulation of adhesion molecules (ICAM-1, VCAM-1, E-selectin). IL-1ra binds 
proinflammatory IL-1 receptors without causing intracellular signaling, thus acting as a 
modulator of inflammation [Dinarello 1998]. 
 
IL-6 is mainly produced by monocytes/macrophages, as well as T and B lymphocytes, 
fibroblasts, endothelial cells, keratinocytes, hepatocytes, and bone marrow cells. It facilitates 
the differentiation of B lymphocytes to plasma cells. IL-6 mediates T cell activation, growth, 
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and differentiation. IL-6 is considered to be the most important inducer of hepatocyte 
synthesis of acute phase proteins. IL-6 also has several anti-inflammatory effects, for example 
stimulating the synthesis of IL-1ra. IL-6 inhibits the synthesis of TNF and IL-1, both of which 
induce synthesis of each other and IL-6 [Akira et al. 1993]. 
Acute phase proteins 
An acute phase protein has been defined as one whose plasma concentration increases 
(positive acute phase proteins) or decreases (negative acute phase proteins) by at least 25% 















Central nervous system 
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IL-4, -5, -9, -13 
 
Figure 1. Summary of cytokine actions. Cytokines are derived predominantly from 
monocytes/macrophages. They are uniquely important in initiating innate immunity 
responses. The phenotype of the subsequent immune response is a function of the 
repertoire of cytokines produced by the responding T-helper lymphocytes. Adapted from 
Borish and Steinke [2003]. 
REVIEW OF LITERATURE 
16 
include infection, trauma, advanced cancer, and rheumatic diseases and other 
immunologically mediated conditions [Gabay and Kushner 1999]. 
 
The changes in the concentrations of acute phase proteins are largely due to their changes in 
their production by hepatocytes. IL-6 is the chief stimulator of the production of most acute-
phase proteins [Akira et al. 1993]. Different cytokine combinations have been found to have 
additive, inhibitory, or synergistic effects. The expression of acute phase protein genes is 
mainly regulated at the transcriptional level, but post-translational mechanisms, such as 
modulation of messenger RNA stability and translation, also play a role [Gabay and Kushner 
1999]. 
 
C-reactive protein is currently the most widely used measurement used in evaluating the 
acute phase response. It is able to bind to phosphocoline and thus recognize some foreign 
pathogens as well as phospholipids of damaged cells, and activate the complement system 
when bound to one of its ligands. Other proinflammatory effects include the induction of 
inflammatory cytokines and tissue factor in monocytes. CRP may also have an anti-
inflammatory effects, by preventing neutrophil adhesion to endothelial cells, inhibiting 
superoxide generation by neutrophils, and stimulating the synthesis of IL-1ra by mononuclear 
cells [Du Clos and Mold 2004]. 
 
Procalcitonin is a precursor of the hormone calcitonin, secreted by the thyroid gland. 
Normally the procalcitonin levels in the circulation are very low. However, very high levels 
are detected in sepsis [Meisner 2002], also in patients who have previously undergone 
thyroidectomy [Assicot et al. 1993]. The source of inflammatory procalcitonin is unknown. It 
is thought to originate from the liver [Nijsten et al. 2000], but also mononuclear cells express 
procalcitonin [Oberhoffer et al. 1999]. 
Adaptive immunity 
Adaptive immunity uses antigen-specific receptors on T and B cells to drive targeted effector 
responses in two stages. First, the antigen is presented to and recognized by the antigen 
specific T or B cell leading to cell priming, activation and differentiation, which usually occur 
within the specialised environment of lymphoid tissue. Second, the effector response takes 
place, either by activated T cells that leave the lymphoid tissue and migrate to the disease site, 
or by activated B cells (plasma cells) that release antibodies into the blood and tissue fluids, 
and thence the infective focus [Parkin and Cohen 2001]. 
 
B and T lymphocytes develop from progenitor cells within the bone marrow. B cells remain 
within the marrow for the duration of their development, but T cells migrate to the thymus at 
and early stage as thymocytes. The production of antigen-specific receptors in both cell types 
is the result of an unusual process of random rearrangement and splicing together of multiple 
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DNA segments that code for the antigen-binding areas of the receptors (complementarity-
determining regions). Gene rearrangement occurs early in the development of the cells, before 
exposure to antigen, which leads to the production of a repertoire of over 10
8
 T-cell receptors 
and 10
10
 antibody specificities, adequate to cover the range of pathogens likely to be 
encountered in life. The creation of new clones of T and B cells continues through life 
[Nemazee 2000]. 
 
The cells that have undergone gene rearrangement and emerge from the thymus and bone 
marrow are naïve, i.e., they have not yet encountered their specific antigen within an immune 
response. Consequently, there are only a few naïve T and B cells capable of recognizing a 
foreign particle and there has to be a system to bring the naïve cells and their targets together. 
The secondary lymphoid tissues of the lymph nodes, spleen, tonsils, and mucosal membranes 
provide the microenvironment for this process, and naïve cells migrate to them. In addition to 
T and B lymphocytes, they contain efficient antigen-presenting cells, and lymphocytes are 
provided with cytokines for maintenance and the second signal that is necessary when 
lymphocyte activation takes place [Guermonprez et al. 2002]. 
T lymphocytes 
Antigens are presented to T cells in association with a self-MHC molecule. The delicate 
process of positive selection of T cells that can react with self-MHC and peptide adequately to 
induce immune responses, but are not excessively MHC-reactive to the extent that would 
cause self-tissue destruction, occurs in the thymus [Parkin and Cohen 2001]. The need for 
expression with MHC ensures that only antigens derived from foreign molecules that have 
invaded the host cell or induced an inflammatory response to activate endocytosis by antigen-
presenting cells, are recognized as foreign. In addition, simultaneous signalling via 
costimulatory molecules is required to induce activation of the T cell [Mueller 2000]. 
Inflammatory mediators induce the upregulation of costimulatory molecules. Therefore a T 
cell is much more likely to be activated if it meets its specific antigen via an antigen-
presenting cell, which has been exposed to an inflammatory environment. 
 
T helper (Th) cells expressing CD4 are the orchestrating cells of the immune response, 
recognising foreign antigen, and activating other parts of the cell-mediated immune response 
to eradicate the pathogen. They also play a major part in activation of B cells. Th lymphocytes 
only recognise exogenous antigen taken up and processed by professional antigen presenting 
cells and presented with MHC class II. Antigen-presenting cells include dendritic cells (the 
interdigitating dendritic cells of the lymph nodes, veiled cells in the blood, and Langerhans 
cells in the skin), B cells, and macrophages [Sprent 1995]. 
 
On stimulation, precursor Th0 lymphocytes become either Th1 or Th2 cells [Swain et al. 
1991]. Th1 cells produce IL-2, which induces T cell proliferation, including that of CD4+ 
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18 
cells in an autocrine fashion. IL-2 also stimulates CD8+ T cell division and cytotoxicity. The 
other major cytokine produced by Th1 cells, IFN-γ, activates macrophages to kill intracellular 
pathogens such as mycobacteria, fungi, and protozoa and induces natural killer cells to 
cytotoxicity. The Th1 cytokines therefore induce mainly a cell-mediated inflammatory 
response. There is a positive feedback loop as IFN-γ stimulates other Th0 cells to become Th1 
and inhibits Th2 differentation. A Th1 response is essential to the host to control the 
replication of intracellular pathogens, but it possibly contributes to the pathogenesis of 
autoimmune disease such as RA. Conversely, Th2 cells produce IL-4, -5, -6, and -10, that 
favour antibody production. IL-4 induces class switching in B cells leading to IgE production, 
and IL-5 promotes positive feedback to induce further Th2 responses and suppress Th1 
differentiation. Thus the Th2 response is associated with allergic disease. 
 
Cytotoxic T cells (Tc) expressing CD8 are involved in antiviral and possibly antitumour 
activity. Endogenous antigens complexed with MHC class I molecules activate Tc cells. 
Because all nucleated cells express MHC class I, any such cell that is infected with a virus or 
other intracellular pathogen, or is producing abnormal tumour antigens can present these 
antigens with class I and be removed by cytotoxic attack. After binding to the target cell, Tc 
cells release cytoplasmic granules at the contact site. these granules contain perforin that 
forms pores to the target cell plasma membrane and granzymes that pass through the pores 
into the target cytoplasm. These enzymes activate caspases that induce DNA fragmentation 
and cell apoptosis. Receptor-mediated apoptosis is also involved, as Tc bind target cell 
surface Fas (death inducing) molecules by their Fas ligand [Alam and Gorska 2003].  
B lymphocytes 
Most B cells remain in the lymphoid tissue and recognise free antigen brought there. 
However, during subsequent infections by the same pathogen B cells can be activated by 
follicular dendritic cells which bear Fc and complement receptors, bind immune complexes 
containing antigen, and trap this to activate the B cell response. 
 
B cells produce antibodies [Edelman 1973]. They neutralise toxins, prevent organisms from 
adhering to mucosal surfaces, activate complement, opsonise bacteria for phagocytosis, and 
sensitise tumour and infected cells for antibody-dependent cytotoxic attack by killer cells. 
Thus, antibodies act partly by enhancing elements of innate immunity. The so-called natural 
antibodies play an important role in this context. They are IgM class antibodies secreted 
without antigenic stimulation, considered to provide a first line of defence against invading 
pathogens [Baumgarth et. al. 2005]. They are often autoreactive, and may also play a role in 
recognition and removal of senescent cells, cell debris, and other self-antigens. Although 
ultimately antibody is the secreted product of activated B cells with the functions listed above, 
early in B cell development it is a membrane-bound molecule that acts as the B cell receptor. 
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In this role the B cell internalises antigen and processes it to act as an antigen-presenting cell 
for T cell responses. 
 
Antigen recognised by the surface IgM of the B cell is internalised, processed, and re-
expressed on the MHC class II molecule of the B cell. This can then present the antigen to a 
primed specific T cell (which recognises a different part of the same antigen). The T cell in 
turn produces cytokines leading to B cell division and maturation to antibody secreting cells 
[Lanzavecchia 1990]. Further T cell interactions induce isotype switching from the initial IgM 
response. Somatic hypermutation occurs, leading to greater antibody diversity. Those cells 
whose surface antibody binds the antigen most avidly proliferate most efficiently. Therefore 
the antibody response matures with increased affinity. The activated B cells leave the 
lymphoid tissue as plasma cells. Some of the activated cells become long-lived memory cells. 
These react rapidly to rechallenge and the characteristic IgG production of the secondary 
response occurs. 
Soluble interleukin-2 receptor 
IL-2 is made by T cells, some B cells and dendritic cells. The major function of IL-2 is to 
promote proliferation of both CD4+ and CD8+ T cells. T cells activated through their antigen 
receptors produce IL-2 and the high affinity IL-2 receptor, thus permitting rapid and selective 
expansion of effector T cell populations. This is achieved through proliferative and anti-
apoptotic mechanisms [Gaffen and Liu 2004]. 
 
The interleukin-2 receptor (IL-2R) is composed of three subunits (Table 1). IL-2Rα (also 
known as CD25 or Tac) constitutes the low affinity receptor, which enhances the affinity of 
IL-2R for ligand by approximately 100-fold but does not contribute to signal transduction. IL-
2Rβ (p75) and IL-2Rγ (γc, p65) subunits are necessary and sufficient for effective signalling. 
Neither IL-2Rβ nor IL-2Rγ alone binds IL-2 detectably, but the IL-2Rβ/IL-2Rγ complex 
comprises the intermediate affinity IL-2 receptor, which is capable of mediating the full 
spectrum of IL-2-dependent activities. IL-2Rβ and IL-2Rγ subunits are employed in other 
cytokine receptors, but sIL-2Rα is exclusive to the IL-2R [Gaffen 2001]. 
 
A soluble form of IL-2Rα is released upon cell activation. Soluble interleukin-2 receptor (sIL-
2R) is a marker of immune activation [Rubin and Nelson 1990]. It is considered to reflect 
Table 1. Compositions of IL-2 receptor complexes. 
IL-2 affinity High Intermediate Low 
Subunit composition αβγ βγ α 
Ability to signal Complete Complete None 
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mostly T cell activation, and it has been suggested that sIL-2R particularly reflects a Th1 type 
response [Berghella et al. 1998]. 
 
sIL-2R is present in low amounts in sera of healthy individuals. Elevated levels have been 
detected in various clinical conditions, including haematological malignancies, infections and 
autoimmune diseases [Rubin and Nelson 1990]. 
Systemic inflammation 
During the very early stages of infection or tissue damage activated macrophages release 
cytokines. Two of these, granulocyte and granulocyte-macrophage colony stimulating factors, 
stimulate division of myeloid precursors in the bone marrow, releasing millions of cells into 
the circulation and causing a characteristic neutrophil leucocytosis. The activation of 
complement generates C3b, which coats the pathogen surface. The neutrophil chemoattractant 
and activator C5a is also produced, and together with C3a and C4a it triggers histamine 
release by mast cells degranulation. This in turn causes the contraction of smooth muscles and 
rapid increase in local vascular permeability. 
 
Substances released from the pathogen and from damaged tissues up-regulate the expression 
of adhesion molecules on vascular endothelium, alerting passing cells to the presence of 
infection (Figure 2). The cell-surface molecule L-selectin on neutrophils recognizes 
carbohydrate structures such as sialyl-Lewis
x
 on the vascular adhesion molecules. The 
neutrophil rolling along the vessel wall is arrested by these interactions. As the neutrophil 
becomes activated, it rapidly sheds L-selectin from its surface and replaces it with integrins 
and other cell-surface adhesion molecules. Integrins bind E-selectin, which appears on the 













Figure 2. The leukocyte adhesion cascade. 
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the cytokines IL-1 and TNF [Repo and Harlan 1999]. Complement components, 
prostaglandins, leukotrienes, and other inflammatory mediators contribute to the recruitment 
of inflammatory cells, as does an important group of chemoattractant cytokines called 
chemokines. The activated neutrophils pass through the vessel walls, moving up the 
chemotactic gradient to accumulate at the site of infection, where they are placed to 
phagocytose any C3b-coated microbes [Ebnet and Vestweber 1999]. 
 
The rolling step is mediated by neutrophil L-selectin and by E- and P-selectins newly 
expressed on inflamed endothelial cells. P-selectin, mobilized to the endothelial cell surface in 
a few minutes following stimulation by thrombin, histamine, or oxygen radicals, interacts 
primarily with P-selectin glycoprotein ligand-1 (PSGL-1). Rolling subsequently involves E-
selectin, which appears on endothelial cells one to two hours after stimulation by IL-1, TNF, 
or LPS. E-selectin counter-receptors include PSGL-1 and E-selectin ligand-1 [Ebnet and 
Vestweber 1999]. E-selectin is shed from the endothelial surface in a soluble form (soluble E-
selectin, sE-selectin), which can be measured as a marker of systemic inflammation [Gearing 
and Newman, 1993]. 
 
Several integrins are implicated in the adhesion of leukocytes to the endothelium and 
migration in the inflamed tissue. Granulocytes and monocytes express CD11b/CD18, which 
upon cell activation undergoes a conformational change resulting in increased affinity. 
Additional CD11b/CD18 molecules are also rapidly translocated to the cell surface from 
intracellular vesicles. Thus, the cell surface expression of CD11b/CD18 can be used as a 
marker of phagocyte activation and systemic inflammation [Repo and Harlan 1999]. 
Rheumatoid arthritis 
Definitions and clinical features 
RA is a chronic systemic inflammatory disease which targets synovial joints, and is often 
accompanied by an array of extra-articular manifestations [Lee and Weinblatt 2001]. RA 
occurs worldwide, increases in incidence with age, and affects women approximately 3 times 
more often than men. The prevalence of RA is estimated at 0.8-1.0% in adult population, and 
the disease continues to cause significant morbidity, disability, and premature mortality. 
 
The presentation and course of RA is variable. Patients most often have an insidious onset of 
symmetrical joint pain, swelling, and morning stiffness that worsens over several weeks. 
Generalized malaise and fatigue accompany active inflammation. 
 
Physical findings in RA include symmetrical joint inflammation early in the course of the 
disease and manifestations of progressive joint destruction with chronic disease. Warmth, 
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swelling, pain, reduced range of motion, and palpable effusions characterise active synovitis. 
Classically, RA causes synovitis in the metacarpophalangeal (MCP) joints and proximal 
interphalangeal (PIP) and metatarsophalangeal (MTP) joints in a symmetrical distribution. 
RA commonly affects the feet, wrists, and knees, as well as the cervical spine, glenohumeral 
joints, and hips. 
 
Extra-articular manifestations of RA include subcutaneous rheumatoid nodules, vasculitic 
skin ulceration, sicca symptoms, pulmonary nodules and pulmonary interstitial fibrosis, 
mononeuritis multiplex, and Felty's syndrome [Turesson et al. 1999]. 
 
The American College of Rheumatology (ACR) has provided classification criteria of RA 
(Table 2) [Arnett et al. 1988]. 
Pathogenesis 
Immunological changes 
Signs of an aberrant immune response, e.g. rheumatoid factor seropositivity, appear many 
years before the onset of clinical symptoms [Aho et al. 1985]. 
Histological changes 
The inflamed synovium shows pronounced angiogenesis, cellular hyperplasia, influx of 
inflammatory leukocytes, and changes in the expression of cell surface adhesion molecules, 
proteinases, proteinase inhibitors, and many cytokines. Synovial changes in the rheumatoid 
joint vary with disease progression [Hitchon and el-Gabalawy 2003]. In the first weeks of the 
disease, tissue oedema and fibrin deposition are prominent and can manifest clinically as joint 
swelling and pain. Within a short period, the synovial lining becomes hyperplastic, commonly 
Table 2. The American College of Rheumatology classification criteria of rheumatoid 
arthritis. For the diagnosis of RA, a patient should have at least 4 of the 7 criteria. Criteria 
1-4 must have been present for at least 6 weeks. 
1. Morning stiffness (1 hour or more) 
2. Arthritis of 3 or more joint areas 
3. Arthritis of hand joints (PIP, MCP, wrist) 
4. Symmetric arthritis 
5. Rheumatoid nodules 
6. Serum rheumatoid factor 
7. Radiographic changes in hand and/or wrist joint 
PIP, proximal interphalangeal joint; MCP, metacarpophalangeal joint. 
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becoming ten or more cells deep and consisting of type A (macrophage-like) and type B 
(fibroblast-like) synoviocytes. The sublining also undergoes striking alterations in cellular 
number and content, with prominent infiltration of mononuclear cells, including T cells, B 
cells, macrophages, and plasma cells. Synovial-vessel endothelial cells transform into high 
endothelial venules early in the course of the disease. 
 
The formation of locally invasive synovial tissue – pannus – is a characteristic feature of RA. 
This tissue is involved in the joint erosions seen in RA [Gravallese 2002]. Pannus is 
histologically distinct from other regions of the synovium and shows phases of progression. 
Initially, there is penetration of the cartilage by synovial pannus composed of mononuclear 
cells and fibroblasts with high-level expression of matrix metalloproteinases (MMPs) by 
synovial lining cells. In later phases of the disease, cellular pannus can be replaced by fibrous 
pannus comprised of a minimally vascularized layer of pannus cells and collagen overlying 
cartilage. 
Cellular mediators  
The synovial membrane is infiltrated by inflammatory cells, primarily CD4+ T cells. The 
predilection for HLA-DR alleles suggests that RA is caused by an unidentified arthritogenic 
antigen [Weyand and Goronzy 1997]. The antigen could be either an exogenous antigen, such 
as viral protein, or an endogenous protein. 
 
Antigen-activated CD4+ T cells stimulate monocytes, macrophages, and synovial fibroblasts 
to produce the cytokines IL-1, IL-6, and TNF and to secrete MMPs through cell-surface 
signalling as well as the release of soluble mediators such as IFN-γ and IL-17. Activated 
CD4+ T cells also stimulate B cells to produce immunoglobulins, including rheumatoid 
factor. The precise pathogenic role of rheumatoid factor is unknown, but it may involve the 
activation of complement through the formation of immune complexes. Activated CD4+ T 
cells express ostroprotegerin ligands that stimulate osteoclastogenesis (Figure 3). 
 
Activated macrophages, lymphocytes, and fibroblasts, as well as their products, can also 
stimulate angiogenesis, which may explain the increased vascularity found in the RA 
synovium. Endothelial cells in the synovium are activated and express adhesion molecules, 
such as E-selectin, that promote the recruitment of inflammatory cells into the joint. This 
process is enhanced by the release of chemokines, such as IL-8, by inflammatory cells in the 
joint [Choy and Panayi 2001]. 
Soluble mediators 
Monocytes, macrophages, fibroblasts, and T cells release numerous cytokines on stimulation. 
TNF and IL-1 are likely to have primary roles in the pathogenesis of RA. The serum and 
synovial concentrations of both cytokines are high in patients with active RA. Furthermore, 
TNF and IL-1 stimulate the release of MMPs and inhibit the production of tissue inhibitors of 
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MMPs, leading to joint damage. TNF stimulates the development of osteoclasts, which are 
responsible for bone degradation (Figure 3). 
Joint damage 
RA is characterized by progressive joint damage that is mediated by several mechanisms 
[Gravallese 2002]. Early erosion of cartilage and bone is associated with the formation of a 
proliferating pannus. The interface between pannus and cartilage is occupied predominantly 
by activated macrophages and synovial fibroblasts that express MMPs and cathepsins. 
 
IL-1 and TNF stimulate the expression of adhesion molecules on endothelial cells and 
increase the recruitment of neutrophils into the joints. Neutrophils release elastase and 
protease, which degrade proteoglycan in the superficial layer of cartilage. The depletion of 
proteoglycan enables immune complexes to precipitate in the superficial layer of collagens 
and exposes chondrocytes. When stimulated by IL-1, TNF, or activated CD4+ T cells, 
chondrocytes and synovial fibroblasts release MMPs, which are thought to be the main 
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Figure 3. Cytokine signaling pathways involved in inflammatory arthritis. Adapted from Choy & 
Panayi [2001]. 
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Treatment 
The goals of treatment in RA are to control inflammation, prevent progressive joint 
destruction, preserve and improve activities of daily living, and alleviate pain. Medical 
treatment includes the use of non-steroidal anti-inflammatory drugs (NSAIDs), disease-
modifying antirheumatic drugs (DMARDs), corticosteroids, and biological response 
modifiers. In addition to drug therapy, nonpharmacological treatment, including patient 
education, physiotherapy, occupational therapy, orthotics, and surgery are important. 
Disease-modifying antirheumatic drugs 
A major transformation in the pharmacological treatment of RA occurred in the 1990s. The 
previous therapeutic approach, termed as the therapeutic pyramid, generally involved initial 
conservative management with NSAIDs for several years; DMARDs were withheld until 
clear evidence of the progressive character of the disease in the face of erosions was seen. 
DMARDs were then added individually in slow succession if the disease progressed. This 
form of treatment has been replaced by a) early initiation of DMARDs and b) use of 
combinations of DMARDs in patients with the potential for progressive disease. The idea of 
early intervention with DMARDs has been validated in a randomised trial [Möttönen et al. 
2002]. 
 
Methotrexate has become the most widely prescribed DMARD. Other commonly utilized 
DMARDs include leflunomide, sulphasalazine, and hydroxychloroquine. Also cyclosporine, 
azathioprine, D-penicillamine, and gold salts remain in use. DMARD monotherapy is often 
only partly effective and poorly tolerated in long term. DMARD combination therapy has 
been explored as a way to maximize therapeutic effect while maintaining a tolerable toxic-
effect profile. Initial randomized controlled trials of monotherapy versus combination therapy 
yielded conflicting results. However, more recently it has been shown that combination 
therapy has clear benefits and tolerable toxic effects in both early and chronic RA. In general, 
the beneficial combinations have included methotrexate and 1 to 3 other DMARDs [Pincus et 
al. 1999]. 
Biological response modifiers 
Biological response modifiers, whose effects are based on directly manipulating cytokines 
central to the pathogenesis of RA, have become an important new class of RA therapeutics 
[Goldblatt and Isenberg 2005]. Currently three biological response modifiers targeting TNF 
are in clinical use. Two of them are monoclonal anti-TNF antibodies. Infliximab is a chimeric 
IgG1 antibody consisting of the antigen-binding region of mouse antibody and the constant 
region of the human antibody, and adalimumab is a recombinant human IgG1 antibody. They 
bind soluble and membrane-bound TNF, thereby impairing binding of TNF to its receptor, 
and also mediate killing of cells expressing TNF. Etanercept is a soluble TNF-receptor fusion 
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protein, composed of 2 dimers, each with the ligand binding portion of p75 receptor linked to 
the Fc portion of human IgG1. The protein binds TNF, preventing it from engaging its 
receptor. In addition, currently in clinical use is anakinra, a recombinant form of IL-1 receptor 
antagonist. 
 
Other promising biological response modifiers not yet in clinical use in rheumatology include 
abatacept, rituximab, and MRA. Abatacept (CTLA4Ig) is a costimulation blocker, consisting 
of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) fused to the heavy chain region of 
human IgG1. Rituximab is a chimeric anti-CD20 monoclonal antibody, which selectively 
depletes B cells by binding to CD20. MRA is a humanized anti-IL-6 receptor antibody, which 
inhibits binding of IL-6 to the IL-6 receptor [Doan and Massarotti 2005]. Biological response 
modifiers developed but abandoned due to inadequate clinical benefit or excessive toxicity 
include monoclonal antibodies against ICAM-1, CD4, and IL-2 receptor, recombinant anti-
inflammatory cytokines, such as IL-4, IL-10, and IL-11, and matrix metalloproteinase 
inhibitors [Keystone 2003].   
 
Biological response modifiers are generally well tolerated and often yield a response even in 
patients refractory to traditional DMARDs. However, multiple adverse events are attributed to 
the biological response modifiers. Also, they are very expensive. Patients treated with anti-
TNF agents are at increased risk of serious infections, most notably reactivation of latent 
tuberculosis, but also listeriosis, Pneumocystis carinii pneumonia, histoplasmosis, 
aspergillosis, and severe Candida infections [Keane et al. 2001]. There is also concern that 
long-term use of anti-TNF drugs may increase the risk of cancer, particularly lymphoma. 
Prognostic factors 
The two main complications of RA are joint destruction and disability. The search for 
prognostic factors has mostly been focused on prediction of joint destruction [Morel and 
Combe 2005, Scott 2000]. 
 
Genetic factors are the ideal prognostic markers because they are present at disease onset and 
are unchanged by treatment. Several genes have been studied in RA. The presence of the 
shared epitope, i.e. an identical short amino acid sequence found in several HLA-DR alleles, 
has been suggested to predict erosive disease. However, the role of genetic markers in the 
prognosis of RA remains unclear and they are too insensitive to be applied in clinical practice 
as guidance in the choice of therapy. 
 
Environmental factors, such as socio-economic status, level of formal education, age at 
disease onset, and lifestyle factors such as smoking, have been implicated in affecting the 
outcome of early RA. However, the results are conflicting and therefore these factors are not 
reliable prognostic factors in early RA. 
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Disease activity at onset is fundamental with respect to the prognosis of RA. In early RA, the 
number of swollen joints predicts joint damage. High erythrocyte sedimentation rate and 
circulating C-reactive protein level are correlated with radiological outcome. 
 
Rheumatoid factor (RF) is associated with poor prognosis in early RA. Seropositive patients 
have a more progressive disease compared to seronegative patients. High level of RF predicts 
more destructive disease. 
 
Other laboratory markers, such as anti-perinuclear neutrophil cytoplasmic antibodies, 
antikeratin antibodies, and anti-cyclic citrullinated peptide antibodies have been shown to 
predict radiographic progression. 
 
Radiological damage at baseline represents the best predictive factor of severe outcome. 
The initial radiographic score consistently predicts radiological damage by approximately 3 
years [Combe et al. 2001]. 
 
Disability at onset measured with the Stanford Health Assessment Questionnaire (HAQ) is 
the most powerful predictor of functional impairment, work disability, and mortality. During 
the first years of the disease, HAQ is associated with clinical inflammation, but later in the 
course of the disease it is also associated with radiological damage. 
 
Clinical remission is the goal of treatment of RA. There are only a few studies that have also 
sought to find prognostic factors for remission. Low disease activity score, HAQ score, 
Ritchie score, and CRP level at baseline were found to predict remission at 3 years in early 
RA [Gossec et al. 2004]. Also the absence of anti-cyclic citrullinated peptide (CCP) 
antibodies and RF at onset has been found to be associated with remission [Bas et al. 2003a]. 
 
However, currently there are no prognostic markers reliable enough for clinical decision-
making. The prognostic markers mentioned above predict disease severity in patient cohorts, 
but not in a single patient. 
Reactive arthritis 
Definitions and clinical features 
Reactive arthritis (ReA) is defined as a sterile synovitis developing after a distant infection, 
usually in the genitourinary or gastrointestinal tract. It belongs to the group of 
spondyloarthropathies (SpA), which also includes ankylosing spondylitis, psoriatic arthritis, 
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arthritis in inflammatory bowel disease, and undifferentiated SpA [Stafford and Youssef 
2002]. 
 
A number of microbes can trigger ReA. These infections affect mostly the mucosal surfaces 
in the gastrointestinal (Yersinia, Salmonella, Shigella, Campylobacter), urogenital 
(Chlamydia trachomatis) or respiratory tract (Chlamydia pneumoniae).  
 
Most commonly the large joints of the lower extremities are affected, but any joint may be 
inflamed. Inflammatory low back pain and stiffness frequently occur. Entesopathies, 
tenosynovitis, or both, are present in a high proportion of cases. The severity of the arthritis 
varies from mild and transient swelling or discomfort to febrile, severely invalidating 
conditions, which may be hard to differentiate from pyogenic arthritis [Toivanen and 
Toivanen 2004]. 
Pathogenesis 
The microbes that cause ReA (Yersinia, Salmonella, Shigella, Campylobacter, and 
Chlamydia) are gram-negative, intracellular pathogens and contain LPS. They cause the 
primary infection in mucosal tissue, and enter the body. A complex host-microbe interaction 
begins. CD4+ T cells are activated and sensitized to bacterial antigens in the intestinal 
epithelium [Sieper and Braun 1995]. 
 
The joint cultures are negative for triggering microbes. However, there is evidence that 
bacterial antigens circulate from the focus of infection to the joints. Bacterial LPS, RNA, and 
DNA are transported to the joints inside phagocytes. The antigens stimulate the sensitized 
CD4+ T cells, which are mostly of the Th2 type in ReA. It can be assumed that a Th1 type 
response would lead to elimination of the pathogens and suppression of arthritis, whereas a 
Th2 type response leads to persistence of microbes and prolonged or chronic arthritis. 
 
HLA-B27 is the strongest predisposing factor for ReA. About 50-80% of patients in hospital 
based series are HLA-B27 positive [Leirisalo et al. 1982]. However, at population level, the 
frequency is considerably lower [Hannu et al. 2002]. Several theories have been suggested 
about the role of HLA-B27 in the pathogenesis of ReA [Toivanen and Toivanen 2004]. HLA-
B27 may enhance the invasion of bacteria or inhibit the killing of intracellular bacteria. HLA-
B27 may also present bacterial antigens in such ways that lead to autoimmunity. However, the 
role of HLA-B27 in ReA remains unclear. 
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Treatment 
Treatment of ReA should be directed at relief of pain, suppression of inflammation, 
maintenance of function, optimal joint protection, and, when appropriate, eradication of 
infection. Patient education about the prognosis and treatment is essential. Joint rest may be 
needed to alleviate pain in severe cases, but generally inactivity and immobilization should be 
discouraged. Physical therapy can be used to regain muscle strength and range of motion. 
 
NSAIDs form the cornerstone of the treatment, providing analgesic and anti-inflammatory 
effects, and should be used over an extended period of time. Corticosteroids may be used as 
intra-articular injections or perorally for short periods of time in severe joint inflammation. 
Treatment with DMARDs should be considered in severe cases of ReA, where polyarthritis 
persists and if progress to ankylosing spondylitis is suspected. Sulphasalazine is the best-
studied DMARD in ReA [Toivanen and Toivanen 2004]. Biological response modifiers have 
been found to be very effective in SpA [De Keyser et al. 2003]. There are also some case 
reports on the efficacy of infliximab in severe acute ReA. 
 
Antibiotic treatment of the triggering infection is only recommended if the presence of 
infection can still be identified at the onset of arthritis. In enteroarthritis, antibiotic treatment 
has not been shown to influence the course of ongoing ReA. In patients with Chlamydia 
trachomatis triggered ReA, treatment with lymecycline resulted in faster recovery [Lauhio et 
al. 1991]. 
Prognostic factors 
The prognosis of ReA is generally considered good. Most of the patients recover within a 
year. However, recurrences triggered by new infections are frequent. Recurrences and chronic 
development are more common in HLA-B27 positive patients. Persistent or recurrent 
urogenital infection or a chronic inflammatory focus in the gut may contribute to the 
progression of acute ReA to chronic SpA. Male gender and positive family history for SpA or 




AIMS OF THE STUDY 
The overall purpose of the present study was to evaluate markers of immune activation as 
predictors of remission in rheumatoid arthritis (RA) and reactive arthritis (ReA). The specific 
aims of the study were: 
 
1. Evaluation of sE-selectin (I, II, III), procalcitonin (II), and CD11b (II) as markers of 
systemic inflammation in rheumatoid arthritis (I, II) and reactive arthritis (II) 
 
2. Evaluation of lymphocyte activation measured by sIL-2R in patients with early (III) and 
refractory (IV) RA 
 
3. Evaluation of lymphocyte activation measured by sIL-2R in patients with acute ReA (V) 
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MATERIALS AND METHODS 
Subjects 
The present study comprises a total of 282 patients with RA and 54 patients with ReA. The 
characteristics of the patients are shown in Table 3. All study protocols were approved by the 
local ethics committees, and the patients gave written informed consent to participate. 
 
The 25 patients with blood-culture positive sepsis serving as reference subjects (study II) 
were recruited at the Emergency Department, Helsinki University Central Hospital, Helsinki, 
Finland, for a previously published study [Takala et al. 1999b]. The criteria for septic shock 
was as defined by Bone et. al. [1992]. 
 
The 51 (study I) and 67 (study II) healthy controls were hospital staff members who were not 
taking medication and had no clinical signs of infection. 
 
Study I comprised consecutive patients with early RA taking part in an ongoing prospective 
study carried out at the Department of Rheumatology, University Hospital, Lund, Sweden 
[Eberhardt et al. 1990]. The patients fulfilled the 1958 American Rheumatism Association 
(ARA) criteria for definite or classical RA [Ropes et al. 1959], duration of joint symptoms 
was less than 24 months, and patients were at least 18 years old on presentation. The 85 
patients included in the present study had serum samples available at entry and at 1, 2, 3, 4, 
and 5 years. 
 
The patients with active disease were offered treatment with DMARDs together with low 
dose (≤10 mg daily) prednisolone, if clinically indicated. Active disease was considered as the 
presence of six or more swollen joints and at least two of the following features: (a) ≥9 tender 
Table 3. Characteristics of the patients 




Duration of symptoms, 
mean (range) 
I RA 85 54 (64%) 52 (18-78) 11.4 (SD 6.6) months 
II ReA 28 10 (36%) 37 (19-58) 3.8 (0.1-12) months 
 RA 16 14 (88%) 45 (29-68) 5.9 (2-12) months 
III RA 157 110 (70%) 47 (20-65) 8.2 (2-23) months 
IV RA 24 15 (63%) 55 (34-76) 14.3 (4-32) years 
V ReA 26 18 (67%) 46 (18-82) 6.8 (0-13) weeks 
n, number of patients; SD, standard deviation; RA, rheumatoid arthritis; ReA, 
reactive arthrits. 
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joints, (b) morning stiffness of ≥45 minutes, or (c) an ESR of ≥28 mm/hour. During the 
follow-up, 51 patients (60%) received DMARDs and 14 patients (16%) received 
prednisolone. 
 
Study II. The patients with RA and ReA were recruited at the Department of Medicine, 
Helsinki University Central Hospital, Helsinki, Finland. They had been referred to the 
hospital for acute joint symptoms. 
 
The patients with RA fulfilled the American College of Rheumatology criteria for RA [Arnett 
et al. 1988] and the duration of symptoms was less than 12 months. At examination, the 
patients had previously received no DMARD treatment. 
 
The patients with ReA had acute mono- or oligoarthritis, and had to have microbiological or 
serological evidence of preceding infection or a history of infection prior to joint symptoms. 
The pathogen was identified in 18 patients (Salmonella, n=8; Yersinia, n=4; Campylobacter, 
n=2; Chlamydia trachomatis, n=2; Chlamydia pneumoniae, n=2). The remaining patients had 
a history of enteritis (n=9) or urethritis (n=1). 
 
Study III. The FIN-RACo (FINnish Rheumatoid Arthritis Combination therapy) trial is a 
nation-wide multi-center, randomized, open parallel-group trial on patients with early RA 
comparing the efficacy and tolerability of treatment with either a combination of three 
DMARDs (initially sulfasalazine, methotrexate, and hydroxychloroquine) and prednisolone 
(COMBI), or monotherapy with a single DMARD (initially sulphasalazine) with or without 
prednisolone (SINGLE) [Möttönen et al. 1999]. The present study included 157 patients (81 
COMBI and 76 SINGLE) whose baseline serum samples were available.  
 
The inclusion criteria were: 1) fulfillment of American College of Rheumatology (ACR) 
criteria for RA [Arnett et al. 1988], 2) age 18-65 years, 3) duration of symptoms <2 years, and 
4) active disease with ≥3 swollen joints, and at least 3 of the following: (a) erythrocyte 
sedimentation rate (ESR) of ≥28 mm/hour or C-reactive protein (CRP) level of ≥19 mg/liter, 
(b) morning stiffness of ≥29 minutes, (c) >5 swollen joints, or (d) >10 tender joints. 
 
Study IV comprises 24 patients with chronic active RA. The patients had failed all 
conventional DMARDs. A total of 19 patients (79%) were on low-dose (≤15 mg/day) 
prednisolone at the start of infliximab. At the start of infliximab, the patients were on various 
DMARDs (Table 4). Despite that, the patients had active disease. After starting infliximab, 
DMARD treatment was continued with minor modifications during the study period. The 
patients received infliximab infusions (3-4 mg/kg) at entry, and at 2 weeks, 6 weeks, 14 
weeks, and 22 weeks. 
 
Study V. A prospective population-based study of the incidence of inflammatory joint 
diseases was carried out between May 1999 and May 2000 in Kronoberg county, Sweden 
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[Soderlin et al. 2002]. All patients with the final diagnosis of ReA (n=26) were selected for 
the present study. ReA was defined as an inflammatory joint disease either preceded by a 
history of infection less than 2 months from the onset of joint symptoms and verified by 
cultures or positive serology, or, in the absence of history of infection, by cultures or serology 
alone. The pathogen was identified in 20 patients (Campylobacter, n=15; Yersinia and 
Chlamydia trachomatis, n=1; Salmonella and Campylobacter, n=1; Campylobacter and 
Streptococcus pyogenes, n=1). The remaining patients had a history of gastroenteritis (n=1), 
urethritis (n=1), respiratory tract infection (n=4), or staphylococcal soft tissue infection (n=2). 
Follow-up and outcome evaluation 
The patients were seen by a rheumatologist at each study visit. A comprehensive medical 
history was obtained and a throrough physical examination was conducted. At entry, clinical 
laboratory tests were done as necessary for diagnosis and evaluation of disease activity.  
During study visits, clinical examinations and appropriate laboratory samples were performed 
for the evaluation of disease activity (Table 5). 
 
In study I, joint inflammation was assessed using the active joint count, defined as the number 
of joints that were swollen and, in addition, tender on palpation or painful on motion. The 50 
joints evaluated included all joints from the Ritchie index [Ritchie et al. 1968], except for the 
neck and the subtalar joints. Functional status was evaluated with a Swedish version of the 
Stanford Health Assessment Questionnaire (HAQ) disability index [Ekdahl et al. 1988], 
where physical function is evaluated with a questionnaire completed by the patient. A score 
describing disability on a scale of 0-3 is calculated based on the answers. The findings in 
 Table 4. DMARDs used at entry by the patients in study IV. 
Therapy n (%) 
Single therapy 15 (62) 
   Methotrexate (MTX)    7 (29) 
   Leflunomide (LEF)    6 (25) 
   Azathioprine (AZA)    1 (4) 
   Podophyllotoxine (CPH82)    1 (4) 
Combination therapy 9 (38) 
   MTX + LEF    1 (4) 
   MTX + CPH82    1 (4) 
   MTX + hydroxychloroquine (HCQ) + CPH82    2 (8) 
   MTX + HCQ + sulphasalazine (SSZ)  + cyclosporine A     1 (4) 
   AZA + gold sodium thiomalate (GST)    1 (4) 
   AZA + SSZ    1 (4) 
   CPH82 + HCQ    1 (4) 
   HCQ + auranofin    1 (4) 
n, number of patients 
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radiographs of hands and feet were scored using the Larsen method [Larsen et al. 1977], 
which employs reference radiographs depicting each joint at five progressive stages of 
destruction. They are used to calculate a total score of 0-200, depicting radiological joint 
destruction. 
 
In studies I and III, remission was evaluated using the ACR preliminary criteria for remission 
[Pinals et al. 1981]. In both studies the fatigue criteria was omitted, in study III also the 
duration criteria. In study V, remission was defined as the absence of swollen and tender 
joints. In study IV the DAS28 disease activity score [Prevoo et al. 1995] was calculated using 
the formula 
 
( ) GHESRSJCTJCDAS ⋅+⋅+⋅+⋅= 014.0ln70.02828.02856.028  
 
where TJC28 and SJC28 are 28-joint tender and swollen joint counts, ESR is erythrocyte 
sedimentation rate, and GH is patient's evaluation of general health on a visual analogue scale 
(VAS). 
Blood samples 
Serum samples were obtained by laboratory personnel, and stored at -20°C (I, II, III, V). In 
study IV, blood EDTA plasma was obtained by centrifugation. The samples were stored at -
20°C for 12-14 years (I), less than 1 year (II), 5-7 years (III), 2 years (IV), and 3-4 years (V) 
before measuring markers of immune activation.  
 
To obtain samples for flow cytometry (II), blood was collected into a polystyrene tube 
(Falcon No. 2058, Becton-Dickinson Labware, Lincoln Park, NJ, USA), supplemented with 
500 µl of pyrogen-free citrate (113 mmol/l; Baxter Healthcare Ltd, Thetford, Norfolk, United 
Kingdom) and prechilled at 0°C. The sample was incubated on ice, and the buffy-coat layer 
was collected and retained on ice until cell labelling. 
Markers of immune activation 
sE-selectin levels in serum (I-III) were measured using a commercially available ELISA kit 
(Bender MedSystems Diagnostics GmbH, Vienna, Austria). The detection limit was 1.6 
ng/ml, with intra- and inter-assay coefficients of variation (CV) of 5.4% and 6.0%, 
respectively. Measurements were carried out according to the manufacturer’s instructions. All 
samples were measured at least in duplicate. Serial dilutions of recombinant sE-selectin were 
assayed on each microplate and linear regression was used to construct a standard curve for 
calculating the sE-selectin levels of the samples. 
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sIL-2R levels in serum (III, V) or plasma (IV) were measured by the Immulite automated 
immunoassay analyzer (DPC, Los Angeles, California, USA). The detection limit was 10 
IU/ml, with intra- and inter-assay CV of 3.3% and 7.2%, respectively. One measurement was 
taken from each sample. The results were automatically calculated using stored reference 
curves. 
 
CD11b expression on neutrophils and CD14-positive monocytes (II) was determined by 
three-colour flow cytometry [Repo et al. 1993]. Aliquots of the buffy-coat cell suspension 
were double-labelled with pretitrated amounts of fluorescein-isothiocyanate (FITC)-
conjugated CD14 (mouse anti-CD14 IgG2b) and phycoerythrin (PE)-conjugated CD11b 
(mouse anti-CD11b IgG2a) or a corresponding control (PE-conjugated mouse anti-keyhole 
limpet haemocyanin IgG2a) antibody (Becton Dickinson, San Jose, California, USA). 
Contaminating erythrocytes were lysed with ice-cold fluorescence activated cell sorting 
(FACS) lysing solution (Becton Dickinson). Leucocytes were suspended in 0.5% 
formaldehyde and stained with LDS-751 (Exciton, Dayton, Ohio, USA), a nucleic acid dye. 
 
A FACScan flow cytometer (Becton Dickinson) and LYSYS II software served for the 
acquisition and analysis of the data. Two separate data sets, one for neutrophils (5×10
3
 LDS-
751-positive events) and another for monocytes (10
3
 CD14-positive events), were acquired 
for each specimen. CD11b expression is reported in relative fluorescence units (RFU), i.e. as 
the median channel of the positively fluorescent cell population. In all experiments, >95% of 
neutrophils and monocytes were CD11b positive. 
 
For each series of experiments, a control blood sample from a healthy volunteer was 
processed in parallel with patient samples. The flow cytometer settings and spectral 
compensations remained unchanged during the study period, and a new lot of each 
monoclonal antibody was compared with the old lot. 
 
Procalcitonin levels in serum (II) were measured by an immunoluminometric assay 
(LUMItest PCT, BRAHMS Diagnostica, Berlin, Germany). Functional assay sensitivity was 
0.3 ng/ml. According to the manufacturer, the intra- and inter-assay CV are 6%-10% within 
clinically relevant PCT levels. Standards of recombinant PCT were assayed in order to 
construct a standard curve for calculating the PCT levels of the samples. 
 
Routine laboratory tests, such as erythrocyte sedimentation rate (I-V), serum C-reactive 
protein (I, II, IV, V), rheumatoid factor (I-V), and HLA-B27 (II, V) were carried out using 
standard methods in conjunction with the study visits. 
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Data analysis 
Study I. The results are given as median or mean and interquartile range (IQR), range or 
standard deviation. Individual clinical and laboratory variables of each patient were plotted at 
one-year intervals, and the area under the curve (AUC) was calculated using the trapezoidal 
rule approximation method and standardised by the length of the study. The patients were 
divided into tertiles based on their sE-selectin AUC values and Jonckheere’s test (a non-
parametric test for trend) was used to evaluate within the tertiles of sE-selectin AUC values 
the ordered alternative hypothesis of the AUC values of the other clinical and laboratory 
variables or the changes in Larsen score. The χ
2
-test was used for categorical variables. The 
patients were also divided into tertiles based on their baseline sE-selectin levels. The outcome 
measures were categorised using the median as the cut-off point. Odds ratios (OR) and 
associated 95% confidence intervals (CI) were calculated using both univariate and 
multivariate logistic regression analysis with robust variance estimates. Sex, age at onset, 
rheumatoid factor, shared epitope, and tertiles of baseline sE-selectin were entered as 
covariates. The Mann-Whitney test was used to assess the differences in the serum sE-selectin 
levels of patients and control subjects. The Wilcoxon test was used to evaluate the differences 
in clinical, laboratory, and radiological findings at entry and after follow-up. 
 
Study II. The results are given as median and range. Statistical comparisons between subject 
groups were performed with the Kruskal-Wallis analysis of variance. Post hoc analysis was 
performed with the Mann-Whitney test, with the Bonferroni correction for multiple 
comparisons. 
 
Study III. The results are given as mean and 95% CI or standard deviation (SD), or median 
and IQR. Receiver operating characteristic (ROC) curves were calculated to define the 
optimal cut-off point for the sIL-2R test in predicting remission. Confidence intervals of area 
under ROC curves were estimated using the bootstrap bias-corrected accelerated method. 
Equality of area under ROC curves were tested using an algorithm suggested by DeLong, 
DeLong and Clarke-Pearson [DeLong et al. 1988]. The optimal cut-off value was defined as 
the level with the greatest sum of sensitivity and specificity. OR with 95% CI for prediction 
of remission by baseline demographic, clinical and laboratory variables were calculated using 
multivariate logistic regression analysis. 
 
Study IV. The results are given as mean change and 95% CI, mean and range or SD, or 
median and range. Pearson correlation coefficient was calculated for serum sIL-2R level and 
baseline DAS28 score. The changes in DAS28 scores, with 95% CI, were calculated. The p-
values for changes in DAS28 scores were calculated by the t-test. The predictive value of 
baseline sIL-2R level for change in DAS28 score at 6 and 22 weeks was calculated by robust 
regression analysis. 
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Study V. The results are given as mean and range. Statistical comparison between the groups 
was made using permutation test with general scores. The normality of variables was 
evaluated by the Shapiro-Francia test. However, as the distribution of sIL-2R levels was 
skewed, bootstrap estimation was used to derive the 95% confidence interval. 
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RESULTS AND DISCUSSION 
sE-selectin as a marker of systemic inflammation in early 
RA (I) 
Table 6 shows the clinical, laboratory, and radiological findings of the patients. Despite the 
favourable clinical course, the joint destruction progressed. The median change (IQR) of the 
Larsen score during follow-up was 30 (6-55) in the whole patient group. 
 
Table 7 presents the AUC values of clinical and laboratory findings according to the tertile 
distribution of sE-selectin AUC values. Serum CRP levels, peripheral blood leukocyte counts, 
and active joint counts all had a statistically significant monotonic increasing association with 
serum sE-selectin level AUC value tertiles. 
 
In this prospective study, serum sE-selectin levels were associated with markers of systemic 
inflammation. Previous studies failed to find such associations [Blann et al. 1995, Littler et al. 
1997, Salih et al. 1999]. However, these other studies were cross sectional and examined 
patients with chronic RA. There was also an association between sE-selectin levels and the 
joint damage process. 
 
Table 8 presents the outcome measures according to the tertile distribution of sE-selectin 
AUC values. The functional outcome (HAQ score at the end of the five-year follow up) had a 
monotonic increasing association with the sE-selectin levels. HAQ score AUC values were 
Table 6. Clinical, laboratory, and radiological findings at entry and after five year follow-up. 
  At entry  After 5 years   
Variables  n Median (IQR)  n Median (IQR)  p 
Active joint count (0-50)  83 7 (3-12)  82 2 (0-5)  <0.001 
HAQ score (0-3)  81 0.8 (0.5-1.2)  81 0.9 (0.4-1.3)  0.060 
Serum sE-selectin level (ng/ml)  85 35.4 (26.4-49.0)  85 25.6 (21.2-36.2)  <0.001 
Serum CRP level (mg/l)  68 11 (0-41)  76 3 (0-28)  0.213 
ESR (mm/h)  83 27 (15-45)  79 24 (10-41)  0.789 
WBC (×10
9
/l)  75 8.1 (6.1-10)  82 6.2 (5.5-7.6)  <0.001 
Platelet count (×10
9
/l)  75 241 (215-317)  80 225 (175-255)  0.001 
Haemoglobin level (g/l)  83 122 (114-133)  82 128 (119-138)  0.025 
Larsen score (0-200)  83 7 (3-13)  82 43 (14-64)  <0.001 
n, number of patients; IQR, interquartile range; HAQ, Health Assessment Questionnaire; 
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count 
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not associated with sE-selectin AUC values. The progression of radiological joint destruction, 
expressed as the change in Larsen scores, was also associated with the sE-selectin levels. 
 
Table 9 shows the results of the multivariate logistic regression analysis of the predictive 
value of baseline sE-selectin tertiles for functional and radiological outcome. The patients 
with baseline sE-selectin levels in the third tertile had an increased risk of having an above 
median HAQ score at five years. 
 
Age, sex, presence of rheumatoid factor or shared epitope, achievement of remission, and use 
of DMARDs or oral corticosteroids were not associated with the sE-selectin AUC values or 
with the baseline sE-selectin levels. 
 
Increased circulating sE-selectin levels might maintain low level microvascular inflammation, 
which may in time result in systemic inflammatory tissue injury. However, in this study on 
patients with early RA with relatively few cardiovascular complications, comorbidity was not 
associated with the sE-selectin levels. This is in contrast with previous findings, which 
showed that raised levels of von Willebrand factor, another marker of endothelial activation, 
were predictive of thromboembolic complications in patients with chronic RA [Wallberg-
Jonsson et al. 1993]. 
Table 7. Clinical and laboratory findings (AUC values) according to tertile distribution of 
serum sE-selectin AUC values 
  Serum sE-selectin AUC, tertiles   
  First  Second  Third   
Variables, AUC  n Median (IQR)  n Median (IQR)  n Median (IQR)  p 
Active joint count (0-50)  26 4 (2-6)  27 4 (2-6)  27 6 (3-8)  0.019 
Serum CRP level (mg/l)  22 10 (0-19)  23 7 (3-25)  23 32 (12-62)  0.012 
ESR (mm/h)  24 27 (14-39)  28 23 (17-33)  28 36 (20-59)  0.114 
WBC (×109/l)  22 6.6 (6.0-7.5)  25 7.1 (6.0-8.5)  25 8.4 (6.3-9.3)  0.037 
Platelet count (×109/l)  22 233 (214-255)  25 234 (216-279)  25 263 (226-312)  0.058 
Haemoglobin level (g/l)  26 127 (122-131)  28 127 (118-135)  28 126 (113-139)  0.522 
AUC, area under curve; n, number of patients; IQR, interquartile range; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate; WBC, white blood cell count 
Table 8. Functional and radiological outcome measures according to tertile distribution of 
serum sE-selectin AUC values 
  Serum sE-selectin AUC, tertiles   
  First  Second  Third   
Variables  n Median (IQR)  n Median (IQR)  n Median (IQR)  p 
HAQ score at 5 years  27 0.8 (0.3-1.0)  28 1.0 (0.7-1.3)  26 1.1 (0.5-1.5)  0.021 
Change in Larsen score  27 28 (4-44)  27 18 (4-52)  28 46 (22-66)  0.038 
n, number of patients; IQR, interquartile range; HAQ, Health Assessment Questionnaire 
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At study entry, the median sE-selectin levels of the patients (35.4 ng/ml, IQR 26.4-49.0, 
n=85) and healthy control subjects (42.8 ng/ml, IQR 28.5-53.5, n=51) were comparable. Four 
patients (5%) had a raised sE-selectin level at entry (range 81.6-105.6 ng/ml). Similar levels 
have been detected in another study of 13 patients with early RA [Veale et al. 1998] and also 
in studies of patients with longstanding RA [Blann et al. 1995, Carson et al. 1994, Voskuyl et 
al. 1995].  
CD11b, procalcitonin and sE-selectin as markers of 
systemic inflammation in acute ReA and early RA (II) 
The results show that peripheral blood neutrophil and monocyte surface density of CD11b 
molecules and serum levels of PCT and sE-selectin in healthy subjects and patients with ReA 
and RA are comparable, and in patients with sepsis are high (Table 10, Figure 4). 
Consequently, these markers may be helpful in discriminating acute ReA and early untreated 
RA from sepsis. 
 
Although CD11b density on neutrophils has been reported as normal in patients with RA 
[Crockard et al. 1992, De Clerck et al. 1995, Felzmann et al. 1991, Lopez et al. 1995, 
McCarthy et al. 1992, McCarthy et al. 1992, Nielsen et al. 1999, Storgaard et al. 1996, 
Watson et al. 1993], reports of increased [Macey et al. 1993, Torsteinsdottir et al. 1999a] and 
decreased values also exist [Crocker et al. 2000, Jones et al. 1994]. These inconsistent 
Table 9. Odds of above median HAQ score at 5 years (cut-off point 0.9) and change in 
Larsen score (cut-off point 29) in multivariate logistic regression analysis 
 HAQ score at 5 years Change in Larsen score 
Covariates OR (95% CI) OR (95% CI) 
Sex (female) 5.51 (1.81 to 16.8) 1.26 (0.45 to 3.50) 
Age at onset 1.02 (0.97 to 1.07) 0.97 (0.93 to 1.01) 
Rheumatoid factor 1.09 (0.33 to 3.57) 2.03 (0.66 to 6.30) 
Shared epitope   
    None 1 1 
    Single 0.41 (0.07 to 2.35) 0.74 (0.09 to 5.92) 
    Double 1.14 (0.21 to 6.23) 3.77 (0.43 to 33.26) 
Baseline sE-selectin tertiles  
    First 1 1 
    Second 2.45 (0.70 to 8.59) 1.17 (0.37 to 3.70) 
    Third 4.18 (1.15 to 15.22) 1.58 (0.43 to 5.80) 
HAQ, Health Assessment Questionnaire; OR, odds ratio; CI, confidence interval 
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findings may derive from differences between patient populations or methodological 
differences. 
 
Several reports exist of high monocyte CD11b density in RA patients [Higaki et al. 1992, 
Highton et al. 1995, Liote et al. 1996, McCarthy et al. 1992, Torsteinsdottir et al. 1999b]. 
Unlike in those of our study, patients in previous studies had advanced RA and received a 
range of DMARDs and corticosteroids. Also, isolation of phagocytes by density gradient 
centrifugation [Repo et al. 1993] and fixation procedures [McCarthy et al. 1994, Repo et al. 
1993] modify CD11b expression. 
 
In patients with ReA, less is known about phagocyte activation. In a recent study, monocytes 
in acute ReA were activated, as evidenced by high CD11b density and the presence of 
messenger RNA for proinflammatory cytokines [Kirveskari et al. 1999]. In the present study, 
monocyte CD11b expression in ReA patients and controls was comparable. Although the 
reason for this discrepancy is unknown, it may involve differences in sample handling. In the 
earlier study, blood samples were anticoagulated with heparin at room temperature, which 
may enhance phagocyte metabolism [El Habbal et al. 1995]. Our results, in agreement with 
Felzmann et al. [1991], also show that neutrophil CD11b expression in patients with acute 
ReA falls within the normal range. 
 
Many of the sepsis patients had normal CD11b expression (Figure 4, A and B). In contrast, 
PCT levels of patients with RA and ReA did not overlap with those of the sepsis patients 
(Table 10; Figure 4, C), indicating that as a sepsis marker PCT was superior to CD11b. These 
results agree with previous results indicating that in infection-free patients with active RA, 
PCT levels are normal [Schwenger et al. 1998]. Although sE-selectin levels in the sepsis 
group were high, they overlapped with those in the RA and ReA groups (Table 10; Figure 4, 
D).
Table 10. Markers of systemic inflammation in patients with rheumatoid arthritis, reactive 
arthritis, sepsis, and healthy control subjects. 
  RA  ReA  Sepsis  Controls 
Variables  n Median (range)  n Median (range)  n Median (range)  n Median (range) 
Neutrophil CD11b, RFU  16 53 (31-95)*  28 50 (29-88)*  25 94 (44-269)  67 50 (29-96)* 
Monocyte CD11b, RFU  16 44 (20-64)*  28 40 (23-81)*  25 91 (27-238)  67 37 (16-80)* 
Procalcitonin, ng/ml  10 0.3 (0.2-0.3)*  21 0.3 (0.2-0.4)*  23 11.7 (0.6-515.0)  12 0.3 (n.a.)* 
sE-selectin, ng/ml  10 71.0 (36.0-145.0)*  20 53.5 (20.0-109.0)*  20 203.0 (61.0-713.0)  10 67.3 (20.0-109.0)* 
*, p<0.01 compared to Sepsis group. RA, rheumatoid arthritis; ReA, reactive arthritis; n, number of patients; RFU, relative 
fluorescence unit; n.a., not applicable. 
 




































































Figure 4. CD11b fluorescence intensity of neutrophils (A) and monocytes (B), together with 
serum procalcitonin (C) and sE-selectin (D) levels. Horizontal lines indicate group medians. 
In charts (A) and (B), lower and upper boundaries of the box indicate the 25th and 75th 
percentiles, and whiskers represent 10th and 90th percentiles. Chart (C) is logarithmic 
scale. Abbreviations: RA, rheumatoid arthritis; ReA, reactive arthritis; n, number of patients. 
Symbols: open circles, arthritides or controls; open squares, sepsis; filled squares, septic 
shock. 
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sIL-2R and sE-selectin as predictors of remission in early 
RA (III) 
At six months, 19 COMBI patients (23% [95% CI: 15 to 34]) and 7 SINGLE patients (9% 
[95% CI: 4 to 18]) (2 on prednisolone) were in remission. Among SINGLE patients, the mean 
baseline sIL-2R levels were 429 U/ml (95% CI: 366 to 614) in patients who entered remission 
and 737 U/ml (668 to 829) in patients who did not enter remission (p<0.001) (Figure 5). 
Among COMBI patients, the respective figures were 660 U/ml (570 to 802) and 739 U/ml 
(672 to 824) (p=0.35) (Figure 5). 
 
COMBI therapy and baseline sIL-2R level <442 U/ml were the only significant predictors of 
remission after six months in logistic regression analysis (Table 11). Figure 6 shows the ROC 
curves of serum sIL-2R level for prediction of remission. Only SINGLE values differed 
significantly from the reference line i.e., AUC 0.50, p=0.003. The difference between AUC 
for SINGLE (0.86 [95% CI: 0.62 to 0.95]) and that for COMBI (0.57 [95% CI: 0.42 to 0.71]) 
was significant, p=0.006. 
 
Thus, low baseline levels of sIL-2R (<442 U/ml) predict remission at 6 months in patients 
with active early RA treated with a single DMARD. The present finding is not in accordance 
with two previous studies in which the baseline sIL-2R levels failed to predict the clinical 
outcome of RA patients treated either with methotrexate [Polisson et al. 1994], or with 
sulfasalazine or parenteral gold [Merkel et al. 1996]. Unlike the present study, both studies 
included patients with longstanding RA, with mean disease duration more than 10 and 5 
years, respectively. Such patients with a long disease duration may be less prone to 
spontaneous or drug induced remissions, which occurs in 10 to 30 percent of patients with 





Figure 5. Baseline sIL-2R levels in single 
disease-modifying antirheumatic drug group 
(SINGLE) and combination drug group 
(COMBI) according to remission after 6 
months. Dots denote group means and 













































































Figure 6. ROC curves of baseline sIL-2R level for prediction of remission at six months in 
SINGLE and COMBI groups. Diagonal dotted line represents reference line (“line of no 
information”). 
Table 11. Logistic regression analysis for the odds to reach remission after six months 
Variable at beginning of study OR (95% CI) 
Combination strategy 4.4 (1.6 to 12.2) 
sIL-2R level <442 U/ml 4.7 (1.4 to 15.2) 
Female sex 1.0 (0.3 to 3.1) 
Age in years 1.0 (0.9 to 1.1) 
Disease duration in months 1.0 (0.9 to 1.1) 
Rheumatoid factor present 1.2 (0.4 to 3.7) 
Erythrocyte sedimentation rate 1.0 (0.9 to 1.1) 
Swollen joint count 1.0 (0.9 to 1.1) 
Tender joint count 0.9 (0.9 to 1.0) 
OR, odds ratio; CI, confidence interval. 
Odds ratios are adjusted for all other variables in 
the model. 
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The respective median (IQR) sE-selectin levels in SINGLE for remission and for 
nonremission subgroups were 33.7 ng/ml (26.9 , 52.2) and 40.8 ng/ml (26.2 , 55.2). The 
corresponding values in COMBI were 43.2 ng/ml (32.2 , 56.4) and 37.9 ng/ml (27.8 , 50.7). 
The AUC values for SINGLE and COMBI were comparable, 0.58 (95% CI: 0.34 to 0.73) vs. 
0.45 (95% CI: 0.31 to 0.61). Neither group differed significantly from the reference line 
(AUC 0.50). In conclusion, baseline sE-selectin used as marker of systemic inflammation did 
not predict early remission in patients treated actively with DMARDs. 
sIL-2R as predictor of treatment response in refractory 
RA (IV) 
The mean serum sIL-2R level was 621 U/ml (SD 325) and mean DAS28 score was 6.3 (SD 
1.0). The serum sIL-2R level did not correlate with the baseline DAS28 score, r=0.24 (95% 
CI: -0.18 to 0.58). This is in agreement with previous studies which have shown poor 
[Beckham et al. 1992, Franke et al. 1997, Salaffi et al. 1995] or no [Tebib et al. 1995] 
correlation between serum level of sIL-2R and clinical activity of RA.  
 
There was a distinct clinical response to infliximab. At 6 weeks, DAS28 scores improved 
(mean score 3.7, SD 1.7), with a mean change of –2.53 (95% CI: -3.08 to -1.95, p<0.001). 
This change was predicted by baseline sIL-2R level (Table 12; Figure 7, a) but not by 
baseline DAS28 score or infliximab dose. Given that the serum sIL-2R level serves as a 
marker to T-cell activation [Rubin and Nelson 1990], our results suggest that enhanced T-cell 
activation is related to delayed response to the infliximab therapy. 
 
At 22 weeks, the mean DAS28 score was 4.0 (SD 1.2), and the mean change from baseline 
was –2.26 (95% CI: -2.75 to -1.77, p<0.001). This change was predicted by neither baseline 
sIL-2R level (Table 12; Figure 7, b) nor baseline DAS28 score or infliximab dose. The 
finding agrees with the previous studies of refractory RA patients treated with methorexate 
for 18 weeks [Polisson et al. 1994] or DMARD naive patients treated with sulphasalazine or 
parenteral gold for 37 weeks [Merkel et al. 1996], indicating no correlation between initial 
serum sIL-2R level and response to the therapy.  
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Table 12. Baseline-adjusted robust regression for baseline sIL-2R predicting change in 
DAS28 score after 6 and 22 weeks. 
  DAS28 change from baseline 
  After 6 weeks  After 22 weeks 
Explanatory variables  Coefficient (95% CI) p  Coefficient (95% CI) p 
Baseline sIL-2R (per 100 U/ml)  0.2054 (0.0035 , 0.4073) 0.047  0.0152 (-0.1872 , 0.2176) 0.88 
Baseline DAS28 score  0.0585 (-0.5327 , 0.6498) 0.84  -0.3067 (-0.8730 , 0.2595) 0.27 
Infliximab dose (mg/kg)  0.1313 (-0.3719 , 0.6346) 0.59  0.0185 (-0.4515 , 0.4885) 0.94 
Constant  -4.995 (-8.708 , -1.2823)   -0.1731 (-3.220 , 2.873)  






























































sIL-2R at baseline (U/ml) sIL-2R at baseline (U/ml) 
a) After 6 weeks b) After 22 weeks 
Figure 7. Baseline serum sIL-2R versus change in DAS28 score from baseline to 6 weeks 
and baseline to 22 weeks. Symbols: filled circle, mean; whiskers, 95% confidence interval. 
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sIL-2R as predictor of remission in acute ReA (V) 
A total of 17 patients (65%) were in remission at 6 months, and 9 patients (35%) still had 
joint symptoms. At baseline, the patients in remission at 6 months had higher sIL-2R levels 
(Figure 8), 891 U/ml (95% CI: 658 to 1123) versus 501 U/ml (95% CI: 436 to 566), p=0.022. 
The baseline sIL-2R level was 528 U/ml (95% CI: 416 to 639) in HLA-B27 positive (n=6) 
and 824 U/ml (95% CI: 618 to 1030) in HLA-B27 negative (n=20) patients, p=0.14. Thus, a 
high serum sIL-2R level in a patient with early acute ReA seems to predict remission by 6 
months. The only previous study of sIL-2R in patients with ReA [Steiner et al. 1995] did not 




































Figure 10. Baseline sIL-2R levels according to remission at 6 months. Symbols: filled circle, 





Limitations of the study 
The studies were based on serum or plasma samples stored for up to 14 years at -20˚C. This 
was recognized while designing the studies, and both sE-selectin and sIL-2R chosen to be 
measured from stored samples are relatively stable molecules able to withstand even storage 
at room temperature for a limited period of time. Therefore it is unlikely that extended storage 
has substantially affected the results. 
 
Another factor that may have an effect on levels of circulating markers is inadequate 
clearance due to renal disease or use of NSAIDs. The possible effect of these factors on the 
results cannot be excluded. In addition, the patients in study IV were on various DMARD 
prior to and during the study period, which may have affected the sIL-2R levels measured or 
response to infliximab treatment. 
Validity of the results 
The patients in study I were chosen from the cohort because they had a full set of serum 
samples available. That is, however, unlikely to have led to a bias. The other studies 
comprised consecutive patients. Thus, the patient samples are representative of appropriate 
patients seen in everyday rheumatological practice. 
 
The common limitation of studies II, IV, and V is the relatively small number of patients, 
which should be taken into consideration while interpreting the results. However, is should be 
noted that compilation of such patient cohorts is rather arduous. 
sE-selectin as a marker of systemic inflammation in early 
RA (I) 
Other investigators [Newman et al. 1993] have shown a correlation between serum and 
synovial fluid concentrations of sE-selectin, and our findings might therefore give some 
support to the hypothesis that E-selectin participates in the pathogenic mechanisms in the 
rheumatoid joint. The synovial  fluid levels are higher in RA than in non-inflammatory joint 
diseases [Koch et al. 1993, Newman et al. 1993]. Furthermore, expression of E-selectin 
molecules occurs in the rheumatoid synovial tissue [Elewaut et al. 1998, Kriegsmann et al. 




The sE-selectin levels at entry and during follow-up were associated with functional status 
after five years. The observed association can be explained, at least in part, by the 
proinflammatory properties of sE-selectin, which might promote joint inflammation and 
thereby compromise physical function of the patient. Furthermore, IL-1, the key mediator of 
systemic inflammation, causes fatigue through its effects on the central nervous system 
[Licinio and Wong 1997]. Fatigue affects the subjective experience of functional ability and is 
reflected in the HAQ score [Scharloo et al. 1999, Wolfe et al. 1996]. 
 
The sE-selectin levels, although within the normal range, may affect chronic inflammation 
and a slight increase may occur, for example in patients with clinically relevant 
atherosclerosis [Fassbender et al. 1999, Frijns et al. 1997]. Similarly, CRP levels, although 
within the normal range, have been shown to predict coronary events [Rifai and Ridker 2001]. 
Given that CRP and sE-selectin are both markers of systemic inflammation, the hypothesis 
can be proposed that sE-selectin levels within the normal range may also reflect smouldering 
inflammation. The clinical relevance of sE-selectin levels is an entirely different issue, and the 
results of this study show that the use of sE-selectin measurements in the clinic cannot be 
advocated owing to their inadequate predictive value. 
CD11b and procalcitonin as markers of systemic 
inflammation in acute ReA and early RA (II) 
In studies comparing CD11b expression on peripheral blood and synovial fluid phagocytes in 
RA patients, higher expression levels have consistently been found on synovial fluid cells 
[Crockard et al. 1992, De Clerck et al. 1995, Felzmann et al. 1991, Lopez et al. 1995]. The 
findings of normal CD11b expression on circulating phagocytes in peripheral blood may 
result from the tendency of activated cells leaving the circulation and homing to the inflamed 
synovium. It is also possible that the activation of phagocytes resulting in elevated CD11b 
expression occurs only after the cells have entered the inflamed synovium. 
 
In sepsis, bacterial components, such as LPS are considered to cause systemic inflammation. 
Patients with ReA have been shown to carry bacterial LPS in circulating phagocytes 
[Granfors et al. 1998]. Such LPS molecules, however, are not necessarily proinflammatory. 
Indeed, phagocytes can deacylate LPS which abolishes many of the inflammatory properties 
of LPS [Repo et al. 1994]. There are data showing that monocytes may generate PCT 
[Oberhoffer et al. 1999]. LPS could stimulate ReA monocytes to produce increased amounts 
of PCT. However, the circulating PCT levels in ReA were found to be normal. Thus, despite 
the spreading of microbial antigens and systemic inflammation in ReA, the laboratory 
markers are different between ReA and sepsis patients. 
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sIL-2R as predictor of treatment response in early (III) and 
refractory (IV) RA 
Low circulating sIL-2R level predicted remission at 6 months in patients with active early RA 
treated with a single DMARD (III). It is possible that in some patients with a low degree of T-
cell activation even a single DMARD is able to induce remission, whereas combination 
therapy appears to be effective even in patients with high T-cell activation. It is also possible 
that low sIL-2R identifies the patients bound to enter spontaneous remission. 
 
With respect to serum sIL-2R levels, the patients with RA refractory to DMARDs in study IV 
were similar to the DMARD naive patients in study III. Thus, low sIL-2R level can be a 
feature of early untreated RA or of patients with active disease despite treatment with various 
DMARDs. Low sIL-2R level may be a marker of a subtype of RA, notoriously known to be 
heterogeneous, and indicate a more rapid and favourable response to treatment. The findings 
of these studies raise the intriguing question whether the patients with high sIL-2R levels, 
denoting high lymphocyte activation, would be particularly suitable for treatment with 
CTLA4Ig [Kremer et al. 2003] or other drugs suggested to play via inhibition of T cell 
activation [Lorenz 2003]. 
sIL-2R as predictor of remission in acute ReA (V) 
In patients with RA, low circulating sIL-2R levels predicted early response to treatment (III, 
IV). However, in patients with ReA, high sIL-2R levels were associated with good outcome 
(V). This discordance is probably related to the different immunopathogenesis of these 
diseases. RA is characterised by a Th1 immune response [Choy and Panayi 2001], whereas in 
ReA a Th2 type response is seen [Smeets et al. 1998]. It has been suggested that secretion of 
sIL-2R is associated with a Th1-type response [Berghella et al. 1998]. Thus, the high sIL-2R 
levels in the ReA patients with a favourable outcome could reflect beneficial Th1 immune 
activation aimed at eliminating the microbe. In patients with RA, however, high sIL-2R levels 
might reflect a harmful Th1 autoimmune response. Interestingly, low sIL-2R levels have been 
observed in patients with chronic spondyloarthropathy [Toussirot et al. 1994] where an 
impairment of T cell activation has been observed [Baeten et al. 2004], as an indirect 
evidence of the failure of immune response to induce remission. 
 
In study V, HLA-B27 positive patients had especially low serum sIL-2R levels. HLA-B27 is a 
strong marker for severity and chronicity of ReA. In hospital-based series, most of the 
patients are HLA-B27 positive [Leirisalo et al. 1982]. The frequency is considerably lower in 
community-based series [Hannu et al. 2002], as also in the present study. HLA-B27 has been 
studied with respect to cytokine production and prognosis of ReA. Of patients with 
Chlamydia induced acute ReA, those with HLA-B27 had lower levels of IFN-γ in synovial 
fluid, which was associated with a chronic course of arthritis [Bas et al. 2003b]. Also, low 
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secretion capacities of TNF and IFN-γ by peripheral blood mononuclear cells by patients with 
acute ReA predicted the persistence of arthritis for more than 6 months [Braun et al. 1999]. 
Taken together, the results above raise a possibility that novel treatment modalities, such as 
immune stimulation with IFN-γ might enhance both microbial elimination and clinical 
recovery at least in some patients with acute ReA. Although the results in the present study 
are preliminary and need to be interpreted cautiously they suggest that sIL-2R aids to identify 
the ReA patients who might benefit from immune stimulation. 
Future prospects 
The results show that sIL-2R is a promising predictive marker in both RA and ReA. In order 
to further analyze the value of this marker, new prospective studies comprising larger 
numbers of patients are necessary. Also other predictive markers should be sought using 
traditional biochemical methods, such as in the present study, and also cutting-edge 
approaches, such as genomics and proteomics. The goal of the research should be to provide 






Activation of vascular endothelium, reflected by circulating sE-selectin levels, was associated 
with joint inflammation and markers of systemic inflammation (C-reactive protein and white 
blood cell count) during a follow-up period of five years. Serum sE-selectin levels during 
follow-up were associated with functional and radiological outcome after five years as well, 
and baseline levels also predicted functional outcome (I).  
 
Patients with acute ReA and early RA have normal CD11b expression levels on phagocytes, 
and normal procalcitonin and sE-selectin levels in serum (II). Elevated levels of these markers 
may be a sign of sepsis. 
 
Low baseline level of circulating sIL-2R predicts remission at 6 months in patients with active 
early RA treated with a single DMARD (III) and rapid response to infliximab treatment in 
patients with refractory RA (IV). 
 
High circulating sIL-2R level in acute ReA is a marker of good outcome (V), possibly 
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